Haleon outlook held steady as organic growth improves in third quarter

Haleon PLC reported a 3.4% organic revenue growth in the third quarter, an improvement from Q2's 3.0%, driven by a balanced contribution from price and volume/mix, with strong performance in Oral Health (6.9%) and emerging markets (7.1%). The consumer health company reaffirmed its full-year guidance for approximately 3.5% organic revenue growth and high single-digit operating profit growth, indicating consistent operational execution and stable outlook for investors.

Analysis

Haleon PLC reported a 3.4% organic revenue growth in Q3 2025, marking an improvement from the 3.0% recorded in Q2. This growth was driven by a more balanced contribution of 1.8% price growth and a notable 1.6% uplift in volume and mix, indicating strengthening underlying demand compared to the previous quarter's 0.5% volume/mix.

All regions contributed positively, with emerging markets leading at 7.1% growth, including double-digit gains in India. Oral Health was a standout performer, achieving 6.9% organic sales growth, primarily fueled by innovation and new product launches across key brands like Sensodyne. The Vitamins, Minerals and Supplements (VMS) category also expanded by 4.9%, supported by strong Centrum demand.

The company maintained its full-year guidance for approximately 3.5% organic revenue growth and high single-digit operating profit growth, contingent on a normal cold and flu season. CEO Brian McNamara highlighted strong in-market execution and continued innovation as key drivers, reinforcing confidence in the company's operational strategy.

Key Decisions for Investors

• Investors should monitor Haleon's continued ability to drive volume/mix growth, particularly given the Q3 improvement from 0.5% to 1.6%, as this indicates healthier underlying demand beyond price increases.
• Given the reaffirmed full-year guidance and strong performance in key segments like Oral Health and emerging markets, HLN appears to be executing effectively, suggesting a stable outlook.
• Prudent investors should track the impact of the upcoming cold and flu season on the company's performance, as it is a stated assumption for achieving the high single-digit operating profit growth guidance.